I-Mab (IMAB)

History and Background

I-Mab (IMAB) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel biologics to treat cancer and autoimmune diseases. Founded in 2015, I-Mab has rapidly built a pipeline of differentiated drug candidates. The company's evolution has been marked by strategic collaborations, clinical trial advancements, and a focus on addressing unmet medical needs in China and globally.

Core Business Areas

• Discovery Research: Focuses on identifying and validating novel drug targets and generating innovative biologic drug candidates.
• Clinical Development: Conducts clinical trials to evaluate the safety and efficacy of drug candidates in various indications.
• Commercialization: Prepares for and executes the commercial launch of approved products in collaboration with partners.

Leadership and Structure

I-Mab is led by a management team with extensive experience in drug development and commercialization. The company has a board of directors providing strategic oversight and governance.

Key Offerings

• Eftrenonacog alfa (Efanesoctocog alfa): A long-acting recombinant factor IX fusion protein for hemophilia B, developed in collaboration with Sanofi. Phase 3 data showed efficacy. Competitors include Alprolix (Bioverativ, now Sanofi) and Idelvion (CSL Behring).
• Lemzoparlimab: A CD47 antibody being developed for multiple myeloma and other cancers. It is designed to minimize interference with red blood cells. Competitors include other CD47 targeting antibodies under development by companies such as Gilead and ALX Oncology.
• Gavnmaglutamab: A Claudin 18.2 antibody being developed for gastric and pancreatic cancers. Competitors include other Claudin 18.2 targeting antibodies being developed by companies such as Astellas.

Industry Overview

The biopharmaceutical industry is characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. The focus is shifting towards precision medicine and innovative therapies.

Positioning

I-Mab aims to be a global leader in the discovery and development of novel biologics, focusing on oncology and autoimmune diseases. Their competitive advantage lies in their differentiated pipeline and strategic partnerships.

Total Addressable Market (TAM)

The global oncology and autoimmune disease markets are substantial and growing. Estimated to reach over $500 Billion by 2030. I-Mab is positioning itself to capture a portion of this market through its novel therapies.

Key Competitors

• GILD
• BMY
• MRK
• AZN
• PFE

Competitive Landscape

I-Mab faces intense competition from established pharmaceutical companies. Its success depends on its ability to develop and commercialize differentiated therapies.

Historical Growth: Data not available.

Future Projections: Data not available, as the company is no longer public.

Recent Initiatives: Data not available, as the company is no longer public.

I-Mab, prior to delisting, aimed to be a global biopharmaceutical innovator, heavily invested in novel therapies for oncology and autoimmune diseases. Its pipeline, while promising, required substantial capital and clinical success to realize its potential. The company's success depended on navigating a highly competitive market and mitigating the risks associated with drug development. Now as a private company, these factors still affect the company, but are no longer available publically.

Data Sources:

• Company Website
• SEC Filings
• Analyst Reports
• Industry Publications

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise.